- Home
- OP vs VRAX Comparison
OP vs VRAX Comparison
Compare OP & VRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- VRAX
- Stock Information
- Founded
- OP 2021
- VRAX 2013
- Country
- OP Greece
- VRAX United Kingdom
- Employees
- OP N/A
- VRAX N/A
- Industry
- OP
- VRAX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- OP
- VRAX Health Care
- Exchange
- OP Nasdaq
- VRAX Nasdaq
- Market Cap
- OP 5.3M
- VRAX 4.7M
- IPO Year
- OP N/A
- VRAX 2022
- Fundamental
- Price
- OP $1.54
- VRAX $0.85
- Analyst Decision
- OP
- VRAX Strong Buy
- Analyst Count
- OP 0
- VRAX 1
- Target Price
- OP N/A
- VRAX $3.00
- AVG Volume (30 Days)
- OP 9.4M
- VRAX 37.2K
- Earning Date
- OP 08-06-2025
- VRAX 02-05-2025
- Dividend Yield
- OP N/A
- VRAX N/A
- EPS Growth
- OP N/A
- VRAX N/A
- EPS
- OP N/A
- VRAX N/A
- Revenue
- OP $25,702,000.00
- VRAX $6,331.00
- Revenue This Year
- OP N/A
- VRAX $5,169.18
- Revenue Next Year
- OP N/A
- VRAX $66.97
- P/E Ratio
- OP N/A
- VRAX N/A
- Revenue Growth
- OP 35.58
- VRAX 7.03
- 52 Week Low
- OP $0.63
- VRAX $0.74
- 52 Week High
- OP $3.17
- VRAX $9.00
- Technical
- Relative Strength Index (RSI)
- OP 50.21
- VRAX 45.02
- Support Level
- OP $1.82
- VRAX $0.74
- Resistance Level
- OP $2.30
- VRAX $0.88
- Average True Range (ATR)
- OP 0.54
- VRAX 0.07
- MACD
- OP -0.06
- VRAX 0.01
- Stochastic Oscillator
- OP 32.93
- VRAX 50.23
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About VRAX Virax Biolabs Group Limited
Virax Biolabs Group Ltd is a biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against world-wide viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.